Ertapenem use while Breastfeeding

Drugs containing Ertapenem: Invanz

Ertapenem Levels and Effects while Breastfeeding

Summary of Use during Lactation

Limited information indicates that single maternal doses of ertapenem up to 1 gram produce low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally, disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush has been reported with beta-lactams, but these effects have not been adequately evaluated.

Drug Levels

Maternal Levels. Five women who were 5 to 14 days postpartum received ertapenem 1 gram daily for 3 to 10 days for acute pelvic infections. Breastmilk samples were obtained before the first dose and twice during the 24 hours after the last dose as well as daily in the morning for 2 to 5 days after the last dose. Milk concentrations during the first 24 hours of the last dose ranged from <0.125 mg/L to 0.3 mg/L. Milk concentration was <0.125 mg/L by day 3 in 4 of the women and after 5 days in the 5th.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Possible Effects on Lactation

Relevant published information was not found as of the revision date.

References

1. FDA Center for Drug Evaluation and Research. NDA 21-337. Clinical pharmacology and biopharmaceutics reviews. 2008;37-40. Accessed 09/19/2008. http://www.fda.gov/cder/foi/nda/2001/21337_Invanz_biopharmr.pdf

Ertapenem Identification

Substance Name

Ertapenem

CAS Registry Number

153832-46-3

Drug Class

• Antiinfective Agents
• Antibacterial Agents
• Carbapenems

Administrative Information

LactMed Record Number

691

Information from the National Library of Medicine's LactMed Database.

Last Revision Date

2010-02-12

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

See Also...

• Ertapenem use during Pregnancy
• Ertapenem Consumer Information
• Breastfeeding Support Group
• Safe Medications during Breastfeeding
• Medicine use while Breastfeeding
• Medicine use during Pregnancy

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.